Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis

James Curtin  
*Technological University Dublin*, james.curtin@tudublin.ie

Thomas Cotter  
*University College Cork*

Follow this and additional works at: https://arrow.tudublin.ie/scschbioart

Part of the *Biochemistry Commons*, and the *Cancer Biology Commons*

**Recommended Citation**
Curtin JF, Cotter TG. Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis. Br J Cancer. 2002 Nov 4;87(10):1188-94. doi:10.1038/sj.bjc.6600612
Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis

J F Curtin1,† and T G Cotter1

1Department of Biochemistry, University College Cork, Lee Maltings, Prospect Row, Cork, Ireland

†Current Address: School of Biological Sciences, Dublin Institute of Technology, Dublin 8, Ireland

*Author for correspondence: Email: t.cotter@ucc.ie

ABSTRACT

Treatment of the hormone refractory prostate cancer cell line DU 145 with sublethal concentrations of chemotherapeutic drugs has been reported to sensitise these cells to Fas mediated apoptosis. However, the mechanism by which this occurs has not been determined. Our group has shown that inhibition of JNK activity completely abrogates the effects of chemotherapeutic drugs. Using anisomycin, a potent JNK agonist, we have demonstrated a role for JNK in Fas mediated apoptosis in DU 145 cells. Inhibition of Caspase 8 and Caspase 9 completely inhibits this process which suggests that DU 145 cells require mitochondrial amplification of the Fas apoptotic signal. Furthermore, we have shown that inhibition of Fas mediated apoptosis is an early event in DU 145 cells, occurring upstream of Caspase 8 cleavage. It is hoped that identifying the target of JNK will allow novel therapies to be developed for the treatment of hormone refractory prostate cancer. Such therapies are especially important because no single or combined treatment to date has significantly prolonged survival in patients with hormone refractory prostate cancer.

Keywords: prostate, apoptosis, CD95, Fas, JNK

INTRODUCTION

Prostate cancer is the second most prevalent malignancy in the EU after lung cancer with about 200000 new cases diagnosed and over 35000 deaths each year. In England and Wales, 15000 new cases and 8000 deaths are registered each year (Parkin et al, 2001). Although the prognosis is good for individuals with localised tumours, 10–20% of patients are diagnosed with metastatic prostate cancer (Crawford et al, 1999). These patients are usually treated with hormone ablation therapy which results in immediate tumour regression and temporary relief for the patient. However, hormone refractory prostate cancer invariably develops within 2–3 years of hormone ablation (Petrylak, 1999). This slowly proliferating cancer is extremely difficult to treat and the prognosis for the patient is generally poor. Over the past 5 years, chemotherapy has been used to improve the quality of life in patients with metastatic, hormone-refractory prostate cancer. No treatment has yet been found that cures the disease or even significantly prolongs survival (Petrylak, 1999).
Apoptosis, or programmed cell death (PCD), is characterised by morphological features including chromatin condensation, nuclear fragmentation, cell shrinkage, membrane blebbing and apoptotic body formation (Kerr et al, 1972). Although a variety of different environmental insults and signalling pathways can stimulate apoptosis in cells, most of these signals converge at a family of cysteine proteases called the caspases. Like many proteases, they are synthesised in an inactive form and cleavage into active caspases is essential for the proliferation of the apoptotic signal. Caspases can be divided into two main subfamilies, initiator caspases and effector caspases (Wolf and Green, 1999). The Fas receptor is a member of the Tumour Necrosis Factor receptor superfamily and is expressed at the plasma membrane in a variety of tissues. Ligation of Fas ligand or a cross-linking antibody to the Fas receptor induces apoptosis in susceptible cells. Fas receptor clustering results in the recruitment and auto-cleavage of the initiator caspase, Procaspase 8, at the plasma membrane. Active Caspase 8 proceeds to cleave downstream cellular targets including the effector Caspases 3 and 7, and the Bcl-2 family member Bid (Peter and Krammer, 1998). Often an amplification step is required for Caspase 3 cleavage and morphological apoptosis. Caspase 8 cleaves Bid into tBid, a pro-apoptotic Bcl-2 family member that induces cytochrome c release and apoptosome formation. This amplification loop through the mitochondrion drives the apoptotic programme in type II cells (Scaffidi et al, 1999b).

DU 145 cells, a hormone refractory prostate adenocarcinoma, are highly resistant to Fas mediated apoptosis in vitro. In a study performed using cell lines derived from prostate tumours with different pathological stages including DU 145, it was observed that ALVA-31 and PPC-1 were sensitive to Fas mediated apoptosis. These were reported to be isolated from primary prostatic tumours. In contrast, the cell lines LNCaP, DU 145 and PC-3 were resistant. These cell lines were reported to be derived from distant metastases. The authors correlated prostate cancer disease progression with resistance to Fas. Furthermore they suggest that this phenomenon may explain, at least in part, the inability to treat hormone refractory prostate cancer (Hedlund et al, 1998). The two other cell lines used in this study, JCA-1 and TSU-Pr1 have since been reclassified as bladder cancer cell lines (van Bokhoven et al, 2001).

In order to study the resistance of hormone refractory prostate cancer to chemotherapy, the effects of chemotherapeutic drugs on DU 145 cells was explored (Uslu et al, 1997; Costa-Pereira and Cotter, 1999). Our group discovered that sublethal concentrations of camptothecin, a novel topoisomerase I inhibitor, sensitised DU 145 cells to Fas mediated apoptosis by 20-fold (Costa-Pereira and Cotter, 1999). Activation of the stress kinase JNK was found to be essential in potentiating Fas mediated apoptosis (Costa-Pereira et al, 2000). In this study, we use anisomycin, a potent activator of JNK, to underscore the role played by JNK in Fas mediated apoptosis in DU 145 cells.

MATERIALS AND METHODS

Cell lines and reagents

DU 145 and Jurkat T cells were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA). Cell culture reagents were purchased from Gibco BRL (UK) with the exception of foetal calf serum (FCS) (Sigma, UK). Anisomycin was purchased from Sigma (UK) and was dissolved in DMSO at a concentration of 5mgml−1. A working stock at 10μgml−1 in RPMI was prepared from the original stock. A FACScan (Beckton Dickinson, BD Biosciences, Germany) and Cell Quest software Version 3.3 (Beckton Dickinson) were used for all flow cytometry assays. Annexin V-FITC was
purchased from Bender MedSystems (Germany) and propidium iodide (PI) from Sigma (UK). TUNEL reagents were obtained from Roche (UK) and JC-1 was purchased from Molecular Probes (Netherlands). The antibodies used in this study were mouse anti-Fas IgM clone CH11, mouse anti-Fas IgG for flow cytometry (Bender MedSystems, Germany), phospho-JNK (Thr183/Tyr185) clone G9 and rabbit anti-Caspase 3 (Cell Signalling Technology, New England Biolabs UK), rabbit anti-JNK1 and rabbit anti-Fas ligand (Santa Cruz, USA), rabbit anti-Bid (BioSource International, USA), rabbit anti-human caspase 8 (R&D Systems, UK) and mouse anti-β Actin clone AC-15 (Sigma, UK). All FITC and R-Phycoerythrin conjugated secondary antibodies were purchased from Sigma (UK) and HRP conjugated secondary antibodies from DAKO (Denmark). The Caspase inhibitors z-IETD-fmk and z-LEHD-fmk were obtained from Calbiochem (CN Biosciences UK). Enhanced Chemiluminescence Reagent (ECL) was purchased from Amersham Biosciences (UK).

**Cell culture and treatment**

DU 145 cells were cultured in RPMI 1640 medium supplemented with 5% FCS, 2mM L-Glutamine in the presence of 10IUml−1 penicillin-streptomycin. Jurkat cells were cultured in RPMI 1640 medium containing 10% FCS, 2mM L-Glutamine and 10IUml−1 penicillin-streptomycin. Cells were cultured at 37°C in a humidified atmosphere with 5% CO2 and were routinely subcultured every 2–3 days. Prior to every experiment DU 145 cells were grown to 75% confluency and Jurkats were resuspended at 0.5 million ml−1. DU 145 cells were pretreated with 250ngml−1 anisomycin for 10min before addition of 200ngml−1 anti-Fas IgM.

**Annexin V binding and propidium iodide uptake assay**

DU 145 and Jurkat cells were incubated with 250ngml−1 anisomycin and 200ngml−1 anti-Fas IgM for 8h. The cells were subsequently harvested, washed once in PBS and resuspended in Annexin V binding buffer (150mM NaCl, 18mM CaCl2, 10mM HEPES, 5mM KCl, 1mM MgCl2). FITC conjugated Annexin V (1μgml−1), which binds specifically to apoptotic cells, was added to each sample and incubated at ambient temperature for 5min. Propidium iodide (50μgml−1), excluded from viable cells, was added immediately prior to reading the samples on the FACScan. Where indicated the Caspase 8 and Caspase 9 inhibitors were incubated for 10min at 50μM prior to treating the cells with anisomycin or Fas.

**DNA fragmentation assay**

TUNEL measures DNA fragmentation using the enzyme Terminal deoxynucleotide Transferase (TdT) to transfer multiple biotin labelled nucleotides to the 3’ hydroxyl groups of DNA. FITC conjugated Avidin can be used to stain this modified label. Using flow cytometry, cells with fragmented DNA in their nuclei display an increased fluorescent signal in the FL-1 channel relative to untreated cells.

DU 145 and Jurkat cells were harvested, washed twice in PBS and fixed slowly in 1% paraformaldehyde (PFA) on ice for 15min. The cells were washed twice in PBS and resuspended in 25μl reaction mixture (TdT buffer, 2.5mM CoCl2, Bio-16-dUTP and TdT enzyme). The DNA labelling reaction was allowed to proceed for 30min at 37°C. The cells were washed twice in PBS and resuspended in 50μl staining buffer (5×SSC, 5% vv−1 dry milk, 1×Avidin-FITC and 1/1000×Triton X-100). The cells were stained for 30min at room temperature in the dark and washed twice in PBS. Flow cytometry and Cell Quest were used to collect and analyse the data.
**Fas receptor expression**

0.5×10⁶ cells were harvested per sample and washed twice in PBS. They were stained for 1h at 4°C with 20μg/ml−1 of the primary antibody mouse anti-Fas IgG. After another two washes with PBS, the cells were stained with the FITC conjugated secondary antibody sheep anti-mouse IgG for 1h at 4°C in the dark. Cells stained with secondary antibody alone were used to compensate for intrinsic fluorescence and non-specific binding of the secondary antibody. The cells were washed twice in PBS and the presence of Fas R was detected in FL-1 using a FACScan flow cytometer.

**Fas ligand expression**

0.5×10⁶ cells were harvested per sample and were fixed slowly in ice cold 1% PFA for 15 min. The cells were permeabilised overnight in 70% ethanol (−20°C) and stained with 2μg/ml−1 rabbit anti-Fas ligand or 2μg/ml−1 rabbit irrelevant IgG in IFATX (4% FCS, 150mM NaCl, 10mM HEPES, 0.1% sodium azide, 0.1% Triton X-100) for 1h at 4°C. Subsequently, the cells were stained for 1h with 12μg/ml−1 FITC-conjugated anti-rabbit IgG in the dark at 4°C. Fas ligand expression was analysed on the FACScan using Cell Quest software.

**Mitochondrial membrane depolarisation**

The lipophilic cation called JC-1 is cell permeable and selectively accumulates in the mitochondria of live cells. When depolarisation of the mitochondria occurs, the emission spectrum of JC-1 changes from 590nm (its aggregated form) to 530nm (its monomeric form) and this can be analysed using flow cytometry. Depolarisation of mitochondria results in an increase in fluorescence in the FL-1 channel, and a concurrent decrease in the FL-2 channel in flow cytometers.

DU 145 cells were harvested, resuspended in RPMI+10% FCS and 2.5μg/ml−1 JC-1 was added. The samples were incubated at room temperature for 20min in the dark, washed twice in PBS and read on the FACScan. Analysis was carried out using Cell Quest software.

**SDS–PAGE and Western blot**

Protein extracts were prepared from cells using RIPA lysis buffer (50mM Tris, pH7.4; 150mM NaCl; 1mM each of NaF, NaVO₄ and EGTA; 1% NP40; 0.25% sodium deoxycholate; 0.2mM phenylmethylsulphonyl fluoride; 1μg/ml−1 each of antipain, aprotinin and chymostatin; 0.1μg/ml−1 leupeptin; 4.0μg/ml−1 pepstatin) and 30μg of protein was loaded in each lane of an SDS polyacrylamide gel. Electrophoresis and Western blotting was subsequently carried out. Non-specific protein binding sites on the membrane were blocked using 5% dry milk in TBS+0.1% Tween-20 for 1h at room temperature. The membrane was stained with primary and peroxidase conjugated secondary antibodies according to the manufacturer’s recommended protocol and labelled protein was detected using ECL.

**RESULTS**

*Anisomycin activates JNK and sensitises DU 145 cells to Fas mediated apoptosis*
The hormone refractory cell line DU 145 is highly resistant to Fas mediated apoptosis. This appears to be a common event during prostate cancer progression. Cell lines isolated from early stages of prostate cancer are usually sensitive to the Fas activating antibody anti-Fas IgM. Those cell lines derived from secondary tumours after hormone ablation therapy are generally resistant to Fas (Hedlund et al, 1998). Our group has previously shown that camptothecin, a Topoisomerase I inhibitor, sensitises DU 145 cells to Fas mediated apoptosis (Costa-Pereira and Cotter, 1999).

Additional analysis identified activation of the stress kinase JNK as an integral event in this process (Costa-Pereira et al, 2000). In order to understand the mechanisms behind this sensitisation process we have used anisomycin, an agonist of the JNK pathway in mammalian cells, which is often used in studies involving JNK because of its specificity and potency in activating the JNK pathway. As expected, we found that anisomycin can act in synergy with Fas to induce apoptosis in DU 145 cells. Phosphatidylserine flipping, an early event during apoptosis was detected with FITC-conjugated Annexin-V using flow cytometry. Propidium iodide was used as a counter stain to distinguish between early and late apoptosis (Figure 1A). Flow cytometry was also used to detect DNA fragmentation, another hallmark of apoptosis, in TUNEL labelled DU 145 cells following incubation with anisomycin (250ngml−1) and anti-Fas IgM (200ngml−1) (Figure 1B). This rapid onset of DNA fragmentation in our system is indicative of a stronger apoptotic stimulus when anisomycin is used to sensitise DU 145 cells to anti-Fas IgM in comparison with other cytotoxic drugs. Extensive DNA fragmentation was only observed after 48h when CPDD and CHX were used (Rokhlin et al, 1997; Uslu et al, 1997). Numerous reports have been described in the literature of both Caspase 8 dependent and Caspase 8 independent JNK activation during Fas mediated apoptosis. We used an antibody specific to phosphorylated JNK to assess the status of JNK activation in DU 145 cells after 1 and 8h incubation with anisomycin (250ngml−1) and anti-Fas IgM (200ngml−1). We verified that JNK is not activated either transiently (1h) or prolonged (8h) with anti-Fas IgM (Figure 1c). As expected, anisomycin was found to stimulate prolonged JNK activation in DU 145 cells. An in vitro kinase assay using radiolabelled 32P was used to verify the activity of JNK (data not shown).

**Fas receptor and Fas ligand are not up-regulated by anisomycin in DU 145 cells**

Various reports have shown that down-regulation of Fas receptor or Fas ligand expression occurs in some cancer cells. In addition, expression of Fas ligand has been reported to increase following JNK activation in Jurkat cells (Herr et al, 2000). This increase in Fas ligand expression caused an increase in the kinetics of Fas mediated apoptosis. We assessed the expression of both Fas receptor and Fas ligand over an 8h period (1,2,4 and 8h) following incubation with anisomycin (250ngml−1) or anti-Fas IgM (200ngml−1). Cell surface Fas receptor was expressed on 95% of DU 145 cells and its expression was not found to change following treatment with anisomycin or anti-Fas IgM (Figure 2A). Similarly, Fas ligand was expressed in 90% of DU 145 cells and expression was not increased in DU 145 cells following incubation with anisomycin or anti-Fas IgM (Figure 2B). Western blot analysis confirmed that the expression of Fas receptor and Fas ligand was not upregulated following drug treatment (data not shown).

**Activation of Caspase 3 during Fas mediated apoptosis**

In order to delineate the mechanisms by which DU 145 cells are sensitised to Fas mediated apoptosis we analysed the major events during Fas mediated apoptosis. Most apoptotic stimuli converge on Caspase 3, a cysteine protease and the main effector caspase during Fas mediated
apoptosis. Once activated, Caspase 3 cleaves a variety of substrates responsible for the morphological and biochemical changes observed during apoptosis (Nicholson, 1999). We found that both anisomycin and anti-Fas IgM treatment alone were insufficient for Caspase 3 activation in DU 145 cells. However, co-incubation of cells with both anisomycin and anti-Fas IgM clearly potentiates the activation of Caspase 3 in DU 145 cells (Figure 3A). Anti-Fas IgM treated Jurkats are used as a positive control for Caspase 3 activation. Flow cytometric analysis confirmed that 70% of DU 145 cells expressed the active form of Caspase 3 following treatment with both anisomycin and anti-Fas IgM (data not shown).

Mitochondrial membrane depolarisation

It has been shown that Fas receptor activation is often not sufficient for direct activation of Caspase 3. These cells, known as type II cells, require an amplification signal through the mitochondrion. Caspase 8 cleaves and activates Bid, a pro-apoptotic Bcl-2 family member. This results in mitochondrial membrane depolarisation, cytochrome c release and amplification of the Fas apoptotic signal through Caspase 9 (Kim et al, 2000). Here we used the voltage sensitive, lipophilic fluorescent probe JC-1 to analyse the extent of mitochondrial membrane depolarisation in DU 145 cells. Depolarisation of the mitochondrion causes an increase in FL-1 fluorescence and a concomitant decrease in FL-2 fluorescence when analysed by flow cytometry (Cossarizza et al, 1993). We found that stimulation of DU 145 cells for 8h with anisomycin (250ngml−1) or anti-Fas IgM (200ngml−1) alone did not result in permeability transition of the mitochondria (Figure 3B). This suggested that Fas mediated apoptosis is inhibited up-stream of mitochondrial depolarisation in DU 145 cells. Incubation of DU 145 cells with both anisomycin (250ngml−1) and anti-Fas IgM (200ngml−1) resulted in mitochondrial depolarisation. We found that incubation of DU 145 cells with 50μM z-LEHD-fmk (a Caspase 9 specific inhibitor) completely abrogated apoptosis when incubated with anisomycin (250ngml−1) and anti-Fas IgM (200ngml−1) (Figure 3C). This suggested that mitochondrial membrane depolarisation and cytochrome c release are essential events for Fas mediated apoptosis in DU 145 cells.

Caspase 8 activation in DU 145 cells

The proximal caspase in the Fas apoptotic pathway is Caspase 8. Recruitment and auto-cleavage of Procaspase 8 occurs following Fas receptor activation in sensitive cells. Active Caspase 8 is tetrameric, consisting of two P14 and two P10 subunits. Using Western blot analysis, we found that Caspase 8 is not cleaved in DU 145 cells following treatment with anti-Fas IgM (200ngml−1) (Figure 4A). Therefore, we concluded that inhibition of Fas mediated apoptosis occurred upstream of Caspase 8 activation in DU 145 cells. Caspase 8 cleavage products were only evident following incubation with both anisomycin (250ngml−1) and anti-Fas IgM (200ngml−1). This was also true for the Caspase 8 substrate Bid (Figure 4B). Z-IETD-fmk (50μM), an irreversible inhibitor specific to Caspase 8, was found to completely protect against apoptosis induced by anisomycin (250ngml−1) and anti-Fas IgM (200ngml−1) (Figure 4C). Interestingly, this inhibitor also abolishes apoptosis associated with anisomycin alone. This suggests that low levels of Caspase 8 activation occur in DU 145 cells following incubation with anisomycin alone. A dose titration of z-IETD-fmk confirmed that this inhibitor specifically inhibits Caspase 8 at 50μM (data not shown). FLIP is a family of proteins structurally related to Caspase 8 that inhibit Fas mediated apoptosis when overexpressed in cells (Scaffidi et al, 1999a). Two main isoforms of FLIP are expressed in cells, a long splice variant (FLIPL)
and a short splice variant (FLIPS). Using Western blot analysis we found that DU 145 cells express FLIPS. However, expression of this caspase 8 inhibitor does not appear to decrease following incubation with anisomycin (data not shown).

DISCUSSION

The sensitivity of prostate cancer cell lines to Fas mediated apoptosis has been shown to correlate with tumour stage, grade and resistance to chemotherapeutic drugs (Hedlund et al, 1998). Our group and others have shown that DU 145 cells are highly resistant to Fas mediated apoptosis. Co-treatment with sublethal concentrations of chemotherapeutic drugs including cyclohexamide (CHX), cisplatin (CPDD), etoposide (VP16) and camptothecin was found to sensitise these cells to Fas mediated apoptosis (Uslu et al, 1997; Rokhlin et al, 1998; Costa-Pereira and Cotter, 1999) independently of new protein synthesis (Frost et al, 1999). Our group subsequently identified a key role for JNK in this process. DU 145 cells were co-treated with camptothecin and anti-Fas IgM and were completely protected from apoptosis by anti-sense oligonucleotides specific for JNK (Costa-Pereira et al, 2000). In addition, camptothecin is a potent activator of JNK and sensitises DU 145 cells to Fas mediated apoptosis to a much greater extent than CHX, CPDD and VP16 (Costa-Pereira and Cotter, 1999). We have shown that anisomycin, a potent activator of JNK in mammalian cells, sensitises DU 145 cells to Fas mediated apoptosis to a similar extent as camptothecin. We felt that because camptothecin is also a topoisomerase I inhibitor and the mechanisms by which it activates JNK are unclear, anisomycin would present a better option for delineating the effects of JNK during Fas induced apoptosis.

Binding of Fas ligand, or Fas activating antibodies, to Fas receptor results in DISC formation and prolonged JNK activation by either Caspase 8 dependent or Caspase 8 independent mechanisms (Chang et al, 1998; Rudel et al, 1998; Charette et al, 2001; Graves et al, 2001). We have shown that stimulating Fas R with anti-Fas IgM alone does not result in JNK activation in DU 145 cells. We found that mitochondrial membrane depolarisation only occurs in DU 145 cells co-stimulated with anisomycin and anti-Fas IgM. In addition Caspase 8 and Bid were only cleaved following incubation with both anisomycin and anti-Fas IgM. This suggests that anisomycin sensitises DU 145 cells to Fas mediated apoptosis at a point upstream of Caspase 8 cleavage, probably during DISC formation.

There are some reports of caspase independent cell death following Fas R activation. These are mediated through kinases such as RIP and ASK1 (Holler et al, 2000; Charette et al, 2001). However, we have shown that both Caspase 8 and Caspase 9 inhibitors completely abrogate apoptosis induced by anisomycin and anti-Fas IgM in DU 145 cells. Therefore, anisomycin sensitised DU 145 cells to apoptosis mediated by Fas that is dependent on both Caspase 8 activity to initiate the pathway and Caspase 9 activity as an amplification step required for Caspase 3 activation and apoptosis.

The principal apoptotic pathway activated by many anti-cancer drugs is the Fas apoptotic pathway. DU 145 cells incubated with toxic concentrations of 9-amino camptothecin were found to increase Fas receptor and Fas ligand expression and decrease c-FLIPS. Apoptosis could be inhibited by transient overexpression of c-FLIPS, suggesting that 9-amino camptothecin induces apoptosis through the Fas apoptotic pathway (Chatterjee et al, 2001). However, we found no evidence for increased Fas receptor or Fas ligand expression following incubation with anisomycin. We did
observe a decrease in Fas ligand expression after apoptotic body formation in cells incubated with both anisomycin and anti-Fas IgM. This is most probably due to the shedding of membrane bound Fas ligand and is irrelevant to the initiation of apoptosis in these cells. We also analysed FLIPS expression but no changes were observed following treatment with anisomycin. Chemotherapeutic drugs have also been reported to activate the Fas apoptotic pathway without upregulation of Fas ligand or Fas receptor. Apoptosis induced by CPDD, VP16 and vinblastine (VB) was shown involve Fas receptor clustering and Caspase 8 activation and was independent of Fas ligand in various colon cancer cells and leukaemia cells (Micheau et al, 1999). It is possible that anisomycin is inducing Fas receptor aggregation independently of anti-Fas IgM but this is highly unlikely in light of our results. It seems more probable that JNK activation enhances Fas receptor aggregation and DISC formation through its interaction with some key regulator of DISC formation in DU 145 cells.

Conventional chemotherapy has been unsuccessful in treating prostate cancer. No single or combined chemotherapy regime has been identified that significantly enhances long term survival. This may be due, at least in part, to the resistance developed to Fas mediated apoptosis in hormone refractory prostate cancer. We have sensitised DU 145 cells to Fas mediated apoptosis using the JNK agonist anisomycin. In addition we have traced the effects of JNK to a point upstream of Caspase 8 cleavage. It is hoped that by understanding this process novel drug targets may be identified that improve the treatment of hormone refractory prostate cancer.

ACKNOWLEDGMENTS

This study was supported by the Irish Cancer Society and Enterprise Ireland.

REFERENCES

Chang HY, Nishitoh H, Yang X, Ichijo H, Baltimore D. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science. 1998;281:1860–1863. [PubMed]

Charette SJ, Lambert H, Landry J. A kinase-independent function of Ask1 in caspase-independent cell death. J Biol Chem. 2001;276:36071–36074. [PubMed]

Chatterjee D, Schmitz I, Krueger A, Yeung K, Kirchhoff S, Krammer PH, Peter ME, Wyche JH, Pantazis P. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short) Cancer Res. 2001;61:7148–7154. [PubMed]

Cossarizza A, Baccarani-Contr M, Kalashnikova G, Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1) Biochem Biophys Res Commun. 1993;197:40–45. [PubMed]

Costa-Pereira AP, Cotter TG. Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis. Br J Cancer. 1999;80:371–378. [PMC free article] [PubMed]

Costa-Pereira AP, McKenna SL, Cotter TG. Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis. Br J Cancer. 2000;82:1827–1834. [PMC free article] [PubMed]
Crawford ED, Rosenblum M, Ziada AM, Lange PH. Hormone refractory prostate cancer. Urology. 1999;54:1–7. [PubMed]

Frost PJ, Belldegrun A, Bonavida B. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis. Prostate. 1999;41:20–30. [PubMed]

Graves JD, Draves KE, Gotoh Y, Krebs EG, Clark EA. Both phosphorylation and caspase-mediated cleavage contribute to regulation of the Ste20-like protein kinase Mst1 during CD95/Fas- induced apoptosis. J Biol Chem. 2001;276:14909–14915. [PubMed]

Hedlund TE, Duke RC, Schleicher MS, Miller GJ. Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate. 1998;36:92–101. [PubMed]

Herr I, Posovszky C, Di Marzio LD, Cifone MG, Boehler T, Debatin KM. Autoamplification of apoptosis following ligation of CD95-L, TRAIL and TNF-alpha. Oncogene. 2000;19:4255–4262. [PubMed]

Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1:489–495. [PubMed]

Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–257. [PMC free article] [PubMed]

Kim TH, Zhao Y, Barber MJ, Kuharsky DK, Yin XM. Bid-induced cytochrome c release is mediated by a pathway independent of mitochondrial permeability transition pore and Bax. J Biol Chem. 2000;275:39474–39481. [PubMed]

Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem. 1999;274:7987–7992. [PubMed]

Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 1999;6:1028–1042. [PubMed]

Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37 Suppl 8:S4–S66. [PubMed]

Peter ME, Krammer PH. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol. 1998;10:545–551. [PubMed]

Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. Urology. 1999;54:30–35. [PubMed]

Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res. 1997;57:1758–1768. [PubMed]

Rokhlin OW, Glover RA, Cohen MB. Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7. Cancer Res. 1998;58:5870–5875. [PubMed]
Rudel T, Zenke FT, Chuang TH, Bokoch GM. p21-activated kinase (PAK) is required for Fas-induced JNK activation in Jurkat cells. J Immunol. 1998;160:7–11. [PubMed]

Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem. 1999a;274:1541–1548. [PubMed]

Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem. 1999b;274:22532–22538. [PubMed]

Uslu R, Borsellino N, Frost P, Garban H, Ng CP, Mizutani Y, Belldegrun A, Bonavida B. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clin Cancer Res. 1997;3:963–972. [PubMed]

van Bokhoven A, Varella-Garcia M, Korch C, Miller GJ. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res. 2001;61:6340–6344. [PubMed]

Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem. 1999;274:20049–20052.
FIGURE LEGENDS

Figure 1
Anisomycin sensitised the androgen independent cell line DU 145 to Fas mediated apoptosis. DU 145 cells were pre-treated with anisomycin (250 ng ml⁻¹) for 10 min before the addition of anti-Fas IgM (200 ng ml⁻¹). Cells were stained with Annexin V and PI (A) or TUNEL (B) after 8 h incubation as described in the Materials and Methods section. Flow cytometry was used to visualise the extent of apoptosis. Data are representative of at least three independent experiments. (C) Anisomycin, not anti-Fas IgM, stimulates prolonged JNK activation in DU 145 cells. Western blot analysis was used to detect active JNK in untreated DU 145 cells, or cells treated with anisomycin (250 ng ml⁻¹), anti-Fas IgM (200 ng ml⁻¹) or both anisomycin and anti-Fas IgM for 1 and 8 h. Total JNK expression was determined to ensure equal protein loading.

Figure 2
Flow cytometric analysis of Fas receptor (A) or Fas ligand (B) expression in untreated DU 145 cells or following 8 h incubation with anisomycin (250 ng ml⁻¹), anti-Fas IgM (200 ng ml⁻¹) or both. Data are representative of at least three independent experiments and similar data were obtained for incubations of 1, 2 and 4 h.

Figure 3
(A) Untreated DU 145 (1) cells or cells treated for 8 h with anisomycin (250 ng ml⁻¹) (2), anti-Fas IgM (200 ng ml⁻¹) (3) or both (4) were stained for Caspase 3 cleavage. Jurkats treated with anti-Fas IgM (200 ng ml⁻¹) for 4 h were used as a positive control (5). (B) Mitochondrial membrane depolarisation (ΔΨ) was detected in DU 145 cells using the lipophilic JC-1 probe, as described previously. ΔΨ was only observed in DU 145 cells treated for 8 h with both anisomycin (250 ng ml⁻¹) and anti-Fas IgM (200 ng ml⁻¹). (C) DU 145 cells were pre-treated with 50 μM z-LEHD-fmk (white columns) or a DMSO control (black columns) for 10 min before treating with anisomycin (250 ng ml⁻¹) and anti-Fas IgM (200 ng ml⁻¹) for 8 h. Apoptosis was assessed by staining the cells with Annexin V-FITC and PI. The error bars represent standard deviation after three independent experiments.

Figure 4
Inhibition of Fas mediated apoptosis occurs upstream of Caspase 8 cleavage in DU 145 cells. (A) Western blot analysis of Caspase 8 in untreated DU 145 cells (1) or following incubation with anisomycin (250 ng ml⁻¹) (2), anti-Fas IgM (200 ng ml⁻¹) (3) or both (4) for 8 h. Untreated (5) and anti-Fas IgM treated (200 ng ml⁻¹ anti-Fas IgM, 4 h) (6) Jurkat cells were used as a positive control for the P14 and P10 Caspase 8 cleavage products. β-Actin was also probed to ensure equal protein loading. (B) Bid expression and cleavage was analysed by Western blot in untreated DU 145 cells (1) or in cells incubated with anisomycin (250 ng ml⁻¹) (2), anti-Fas IgM (200 ng ml⁻¹) (3) or both (4) for 8 h. Jurkats untreated (5) or treated with anti-Fas IgM (200 ng ml⁻¹) for 4 h (6) are used as a positive control. (C) DU 145 cells were pre-treated with 50 μM z-IETD-fmk (white columns) or a DMSO control (black columns) for 10 min before treating with anisomycin and anti-Fas IgM as before. Apoptosis was determined by staining with both Annexin V and PI after 8 h. Data is representative of three independent experiments.
Figure 1

A

Apoptosis

- Untreated
- Anisomycin
- Anti-Fas IgM
- Anisomycin and anti-Fas IgM

B

TUNEL positive

- Untreated
- Anisomycin
- Anti-Fas IgM
- Anisomycin and anti-Fas IgM

C

| Time (hours) | Untreated | Anisomycin | Anti-Fas IgM | Anisomycin and anti-Fas IgM |
|-------------|-----------|------------|--------------|----------------------------|
| 1           | 1         | 1          | 1            | 1                          |
| 8           | 1         | 1          | 1            | 1                          |

Phospho JNK

- P54
- P46

JNK

- P54
- P46
Figure 2
Figure 3
Figure 4

(A) Western blot analysis of ProCaspase 8, active Caspase 8, and Actin. The blot shows bands for each protein in different lanes.

(B) Western blot analysis of Bid and tBid. Lanes 1 to 6 show variations in the expression levels of these proteins.

(C) Bar graph showing the percentage of apoptosis in different treatment conditions: Untreated, Anisomycin, Anti-Fas IgM, and Anisomycin and anti-Fas IgM. The graph indicates a significant increase in apoptosis with the combination treatment.